❖❖ Scientific
❖❖ Research

*TP*53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma

Ligia Richter[1,2], Marcelo Buzzi[2*], Carmela Dantas-Barbosa[2,3]

[1]Faculdade LS—Coordenação do Curso de Enfermagem, Setor D Sul, Lote 5, Taguatinga Sul, DF, Brasil; [2]Laboratório de Bioquimica Analítica, Patologia Molecular, Rede Sarah de Hospitais de Reabilitação, Brasília, DF, Brasil; [3]Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052—CNRS 5286, Centre Léon Bérard, Cheney D, 28 Rue Laënnec, Lyon, France.
Email: ligia.richter@gmail.com; *mbuzzi@sarah.br; carmeladantas@hotmail.com

ABSTRACT

Osteosarcoma is a rare and highly malignant tumor that usually affects adolescents and young adults. Despite current management protocols, up to half of patients succumb to the disease. Moreover, there is no well-characterized molecular marker for diagnosis and prognosis. *TP*53 alterations have been associated with a poor prognosis in many cancers. The aim of this retrospective work was to find out whether *TP*53 functional status predicts response to neoadjuvant chemotherapy and thus may help treatment decision for osteosarcoma patients. Seventeen biopsies of osteosarcoma patients receiving primary metotrexate, cisplatin and adryamicin chemotherapy followed by surgery were analyzed. *TP*53 exons 5 - 9 mutations were screened. Among 17 biopsies, 4 (23.5%) displayed *TP*53 mutations: 3 deletions and one single-nucleotide substitution. The presence of *TP*53 gene mutation does not correlate with resistance to chemotherapy according to histological Rosen grade and nevertheless is associated with patient's age in a significant manner (p < 0.05). The presence of non-mutated *TP*53 is not entirely specific for a good prognosis. We found no evidence that *TP*53 mutations predict chemoresistance in osteosarcoma patients more over the overall survival curve, followed for more than 12 years, showing no difference between patients with tumors harboring wild type or mutated *TP*53 gene (p < 0.5). Further analysis to identify other genes that can influence chemotherapy response and clinical outcome in osteosarcoma is needed to improve patient treatment.

Keywords: Osteosarcoma; Chemoresistance; *TP*53 Gene

1. Introduction

Osteosarcoma is the commonest primary bone cancer in children and young adults. Osteosarcoma presents a peak of incidence at the age of 15 - 19 years that coincides with the growth spurt. The estimated incidence rate worldwide is 4 million/year. It is highly malignant, characterized by a high potential to metastasize [1]. These tumors typically arise in the metaphyseal regions of long bones. A preference for the distal femur, proximal tibia and proximal humerus is observed [2]. Almost all osteosarcomas are high grade and have a poor prognosis. Pa-

tients diagnosed with osteosarcoma usually present a large tumor and numerous lung micrometastases which markedly decrease the potential for cure [3]. The use of multiple chemotherapy agents pre- and postoperatively has significantly improved the outcome in the last 30 years, leading to a 5-year disease-free survival for patients with localized tumors in the range of 20% to 60% range [4]. Despite these improvements, approximately 30% of patients with localized disease and 60% of patients with pulmonary metastases succumb to the illness. Osteosarcoma is a complex neoplasia. Cytogenetic analysis has revealed multiple chromosomal rearrangements with a high degree of aneuploidy, gene amplifica-

*Corresponding author.

tion, and multiple unbalanced chromosomal rearrangements without a typical translocation, as it can be seen in other sarcomas [5]. Osteosarcoma markers are required to further characterize this complex, multifactorial neoplasia and improve diagnosis and prognosis.

The *TP*53 gene was defined as the tumor suppressor gene due to its ability to suppress the malignant growth of transformed cells as well as tumors [6]. The *TP*53 gene locates in chromosome 17 (17p13), a region frequently lost in tumors (LOH) and extensive *TP*53 mutation searches revealed that over 50% of human tumors carry mutations in this gene [7]. The majority of the *TP*53 mutations are missense mutations occurring in the highly conserved DNA binding domain of *TP*53 (exons 5 - 8), plus exon 9 [8]. According to IARC *TP*53 mutation database, exons 5, 7 and 8 encompass 30, 26 and 24% of all *TP*53 mutations respectively. Exon 10 harbors only 1.1% of reported *TP*53 mutations [9]. Of Li-Fraumeni family members, who present an increased risk for development of cancers, including osteosarcoma, it was observed a correlation between tumor type, family structure and *TP*53 mutation type [10].

*TP*53 is a transcription factor which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism [11]. *TP*53 also fulfills functions during development in normal tissues [12] and in response to inflammation [13]. The p53 protein is expressed at lower levels in normal cells compared to transformed cells where higher levels of p53 was observed, suggesting that p53 can contribute to transformation and malignancy. Many attempts to establish *TP*53 mutations as a tumor marker have been done and the results are often contradictory. It is difficult to compare all the studies, because different methodologies have been employed. Immunohistochemistry does not allow the precise identification of the mutation. DNA sequencing revealed that in human cancers, >1800 distinct *TP*53 missense mutations have been identified. In breast cancer, it was demonstrated that *TP*53 mutation is a marker of biologically aggressive disease [14] and a response to therapy and survival [15]. The correlation between p53 protein functional status and a response to neoadjuvant chemotherapy was demonstrated in head and neck squamous cell carcinoma (HNSCC) in the oral cavity. The results indicate that the p53 loss of function may predict a significant low rate of complete remission and suboptimal response to cisplatin-based neoadjuvant chemotherapy in patients with oral cavity SCC [15]. The purpose of this paper is to investigate whether *TP*53 mutational status predicts a response to neoadjuvant chemotherapy and thus may help treatment decision in osteosarcoma patients.

2. Material and Methods

2.1. Patient's Selection

Patients with a confirmed diagnosis of osteosarcoma, at any age of both genders that had the biopsies effectuated in our center (Sarah Network of Hospitals, Brasília, Brazil), without previous treatment of chemotherapy or radiotherapy, were eligible for the study. Both fresh tissue and paraffin embedded biopsies were considered. To be included patients should be submitted to the treatment comporting neoadjuvant chemotherapy, followed by surgery and adjuvant chemotherapy according to the protocol established in May 1996. Of the 33 eligible patients, 15 were excluded due to insufficient DNA quantity and one patient left our institution before the chemotherapy treatment. The remaining 17 patients were analyzed in the present work. This study was previously approved by the Sarah Hospital Ethics Committee.

After neoadjuvant chemotherapy, all patients were radiologically re-evaluated and surgery of primary tumor was performed. The type of surgery (amputation or limb salvage) was chosen according to the location and extension of the tumor.

To evaluate chemotherapy response, pathologists reviewed histological material to determine the primary tumor response according to a method previously described [16]. Responses were defined as "good" (>95% tumor necrosis) or "poor" (<95% tumor necrosis).

2.2. *TP*53 Gene Amplification

Genomic DNA was extracted from 50 mg of frozen tissue or from 3 to 6 10 µM sections of formalin-fixed, paraffin-embedded blocks using the QIAamp DNA Mini Kit (Qiagen). PCR analysis of exons 5 to 9 was performed using the primers shown in the **Table 1**. *TP*53 exons were amplified during 30 cycles of 94°C for 45 s, 65°C for 45 s and 72°C for 1 min in a 25 µl volume reaction containing from 50 to 200 ng of genomic DNA, 1.5 mM

Table 1. *TP*53 primers sequence.

Primer	Sequence 5'→ 3'	Amplicon Size in bp
E5-53-A	ctcttcctgcagtactcccctgc	211
E5-53-B	gccccagctgctcaccatcgcta	
E6-53-A	gattgctcttaggtctggcccctc	185
E6-53-B	ggccactgacaaccacccttaacc	
E7-53-A	gtgttctctcctaggttggctctg	139
E7-53-B	caagtggctcctgacctggagtc	
E8-53-A	acctgatttccttactgcctctggc	200
E8-53-B	gtcctgcttgcttacctcgcttagt	
E9-53-A	gcctctttcctaggactgcccaac	102
E9-53-B	cgcaagacttagtacctgaagggtg	

of MgCl$_2$, 0.2 mM dNTP's, 50 μM of each primer and 0.3 U of Taq DNA Polymerase Platinum (Life Technologies).

2.3. Single Strand Conformation Polymorphism (SSCP) and Sequencing Analysis

The single strand conformation polymorphism (SSCP) analysis was performed using the PhastSystem automated electrophoresis apparatus (GE Healthcare/Amersham Pharmacia) and 12.5% and 20% polyacrilamid gels. The run settings were adapted from Kurvinen and coworkers (1995) [17]. Pre-run: 400 V at 10 mA, 2.5 W, 100 Avh; gel loading: 400 V, 1 mA, 2.5 W, 2 Avh, separation: 400 V, 10 mA, 2.5 W, 400 Avh*. All runs were performed at 15˚C. *Avh (accumulated volts per hour) the run time varies according to the DNA size. Exon 5: 300 Avh, Exon 6: 350 Avh, Exon 7: 350 Avh, Exon 8: 300, Avh, Exon 9: 200 Avh.

After electrophoresis the gels were silver stained with the Plus-One DNA Silver Staining kit (GE Healthcare/ Amersham Pharmacia) following manufactures' indications. Using a vacuum gel drying system the gels were dry with Whatman paper. Samples with mutations were identified by the presence of an abnormal electrophoretic migration pattern in comparison with a control carrying wild-type (wt) *TP*53 and were further excised from the gel, for PCR reamplification. The excised band was placed in a 1.5 mL tube, following the addition of 100 μl of water the material were frozen, macerated and heated at 100˚C for 10 minutes. Following a 10,000 *g* centrifugation for 10 minutes the supernatant were transferred to a new tube and 5 μL of it used for PCR reamplification in only 20 PCR cycles. After checking in an agarose gel for the presence of a PCR product, the material was cloned into a pGEM-T Easy vector (Promega). Plasmid purification was performed using the Kit Flexi Prep (GE Healthcare) according to instructions.

The sequencing reactions were prepared using the universal primer (Promega) and the Big Dye Terminator kit (Applied Biosystems), following manufacturers' instructions. Sequencing reactions were resolved in the ABI310 automatic sequencer (Applied Biosystems) Sequence alignments and translations were made with BioEdit software.

2.4. Statistical Analysis

The association between *TP*53 gene mutations and the response to chemotherapy was calculated using the Fisher's two-tailed exact test. Students' test was applied to compare ages. The criterion for statistical significance was α = 0.05. Kaplan and Meier survival curves and statistical analyses were conducted with GraphPad Prism software (GraphPad Software).

3. Results

Seventeen patients aged 10 - 75 years (median 17 years) entered the study. Ten patients were male (59%) and 7 female (41%). Sixteen patients had an osteoblastic tumor and only one patient had a chondroblastic subtype.

We selected only biopsies of primary tumors before treatment aiming to correlate the *TP*53 status to the neoadjuvant treatment response. The identified somatic mutations associated with hotspot region from the tumor suppressor gene *TP*53 are presented in **Table 2**. Among the 17 biopsies, 4 (23.5%) displayed *TP*53 mutations. In total, 6 mutations were identified in 4 osteosarcoma tumor samples: The patient 2 presented deletion of exon 9, Ex9 c.924_936del102, patient 14 presented a silent mutation at position E x 7 c.697 C > T and a deletion at position E x 7 c.732del1 corresponding to codon 244 which engender a frameshit. The patient 25 also harbors a silent mutation at position E x 7 c.703 C > A single-nucleotide substitution and a serine→ cysteine substitution at codon 241 (E x 7 c.722 C > G S241C). For these patients, the mutations can lead to a loss of function of p53 protein. The patient 30 presented a deletion in intron 7 at position In7 c14115del1.

The patients included in this study were treated with the protocol established in the Sarah Hospital in May 1996 that consisted of a neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. The drugs concentrations were estimated after a detailed clinical evaluation of patients. Parameters such as body surface, age, eventual diseases, clinical and laboratorial conditions were taken in account before the beginning of treatment and between each cycle. The goal of neoadjuvant chemotherapy is to shrink the cancer. The osteosarcoma neoadjuvant chemotherapy is composed of a high-dose of Metotrexate (12 g/m^2 of body surface area), cisplatin at 120 mg/m^2 of body surface area and Adriamycin at 75 mg/m^2 of body surface area and the schedule was as follow: first and second weeks: Metotrexate, third week: Cisplatin and Adriamycin, 4th and 5th weeks: rest, during 3 cycles.

The four mutated samples presented the tumor necrosis rate under 95% (**Table 3**) that lead us to conclude that none of those samples presented a good response to the chemotherapy. Nevertheless, 10 other samples also presented a tumor necrosis rate under 95%, indicating a bad response to the chemotherapy. Only 3 samples had a good response (>95%). However there is no correlation between *TP*53 mutation and response to chemotherapy, p = 1.2 (p > 0.05), that means the difference is not significant for this population. The response to the neoadjuvant chemotherapy is summarized in **Table 2**. There is a sig-

*TP*53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin
Chemotherapy in Resected Osteosarcoma

47

Table 2. Clinical and molecular features of osteosarcoma patients.

Patient N°.	Histological subtype	Age (years)	Sex	*TP*53 gene status	Mutation type	Effect type	Tumoral Necrosis %	Status*	Duration of follow up (months)**
1	Osteoblastic	12	M	WT			78	AWD	164
2	Osteoblastic	75	F	Ex9 c.924_936del102	deletion	frameshift	−5	DOD	6
3	Osteoblastic	12	F	WT			100	NED	183
4	Chondroblastic	23	M	WT			73	NED	175
6	Osteoblastic central high grade	18	F	WT			75	DOD	14
9	Osteoblastic central high grade	17	M	WT			88	DOD	11
11	Osteoblastic	16	M	WT			49	DOD	11
12	Osteoblastic	13	F	WT			−10	DOD	21
14	Osteoblastic	16	M	Ex7 c.732del1	deletion	frameshift	70	AWD	140
22	Osteoblastic	20	M	WT			30	LFU	---
23	Osteoblastic	10	F	WT			95	NED	150
24	Osteoblastic	17	M	WT			70	NED	130
25	Osteoblastic	24	M	Ex7 c.722 C > G S241C	substitution	missense	70	NED	130
28	Osteoblastic	17	M	WT			95	NED	127
30	Osteoblastic	19	F	In7 c14115del1	deletion	intronic	87	AWD	123
31	Osteoblastic	13	F	WT			89	AWD	153
33	Osteoblastic	18	M	WT			85	AWD	140

*AWD = alive with disease, DOD = dead of disease, NED = no evolutive disease, LFU = lost of follow-up. **Duration of follow up until death for DOD or last consultation for AWD and NED, in December 2011.

Table 3. Fischer test for variables: mutated and wild type *TP*53.

*TP*53	Tumoral necrosis rate		
	< of 95%	> of 95%	Total
Mutated	4	0	4
Wild type	10	3	13
Total	14	3	17

Figure 1. Kaplan-Meier overall survival curves stratified by *TP*53 mutation status (N = 17).

nificant correlation between patient age and *TP*53 mutations. Patients harboring *TP*53 mutations are older (median 21.5 years) than those that do not present *TP*53 mutations (median 17 years), p = 0.03 (p < 0.05) with Student's test.

It is worth to note that our follow up of patients reached 12 years or more. It is very rare to find such a long last follow up in the literature. Considering this, we have observed that Kaplan-Meier overall survival curve for patients with *TP*53 mutations are similar to those for individuals with wild type *TP*53, in conclusion there is no difference in survival rat between patients harboring *TP*53 wild type or mutated forms (Log-rank test, p = 0.8872). Nevertheless, considering our small sample size those values need to be carefully interpreted (**Figure 1**).

4. Discussion

Many molecular alterations have been described in osteosarcoma; nevertheless few researchers could establish an association with a favorable prognosis related to a molecular alteration. Even considered as a rare disorder 0.4/100,000[1] in the Sarah Hospital, osteosarcoma is the most frequent neoplasia. One retrospective study effectuated from 1982 to 1996 revealed that the event free survival of 5 years is 54% for patients without metastasis at the diagnostic, and 29% for those presenting metastases. These data differ significantly from those related in the literature.

The suppressor gene *TP*53 has been investigated in many human neoplasias and is altered in about half of it [18]. Many different alterations have been reported including breaks, punctual mutations and deletions.

The *TP*53 SSCP analysis after PCR amplification revealed conformational changes in 5 patients and sequencing analysis confirmed the presence of mutations in

4 out 5. The SSCP is an efficient method for screening genetic variations, including single mutations. The sensibility allows detecting between 80% to 90% of the mutations in 200 - 400 bp length DNA fragments [19]. It is an affordable method for institutions that do not dispose of a high throughput sequencer.

Our analysis of *TP*53 mutations extended from exons 5 to 9, a region that encompasses about 90% of the mutations [8]. We found mutations in 23.5% of our patients. In osteosarcoma, there are no consensual data concerning the *TP*53 mutations rate and the response to chemotherapy. In a study published in 1998, Goto and coworkers (1998) observed *TP*53 mutations in 41% of the samples, and among them, 15% were good responders while 64% of patients without *TP*53 mutations presented a good response, with a significant correlation (p < 0.05). They considered as good responders who presented tumoral necrosis rate >90% [20]. This criterion is different from those suggested by Rosen and coworkers (1993) and adopted by us in this study, in which the good responders present >95% of tumor necrosis rate [21].

Radig and coworkers (1996) analyzed 40 osteosarcoma patients and found *TP*53 mutations in 19%. In another study, published in 1998, the same group found 15.7% of mutated osteosarcomas which do not correlate with tumor progression [22]. In a large study containing 272 primary osteosarcomas, *TP*53 mutation was observed in 22% of patients without the correlation of tumor progression [23]. The mutation rate varying from 13.3% [24] (associated with disease free survival), 18% [25], and up to 26.5% [26] has been reported. In a study with a large cohort of 196 osteosarcoma patients, *TP*53 mutations were observed in 19.4% of osteosarcoma patients, and no correlation with p53 mutations and prognosis were observed, nevertheless patient age was the only factor that varied with *TP*53 gene status (p < 0.05) [27]. We confirmed this data. In our study, *TP*53 mutation status was not predictive of chemoresistance; suggesting that chemotherapy response is independent of the *TP53* gene. Nevertheless, the mutation rate could be associated with patient age (p<0.05), as already described [26,27].

A very surprisingly result was observed when we compared the overall survival rate between osteosarcoma patients with *TP*53 wild type and mutated *TP*53. In our cohort, mutated patients have the same live span with patients harboring wild type *TP*53. It is interesting to note that the follow-up over 15 years, as we have described, is very rare to see in the literature. Nevertheless, the sample size of the current study was too small to draw definitive conclusions regarding the relationship between clinicopathologic features and p53 changes. Studying the expression of IDH1 and *TP*53 in osteosarcoma, Hu and coworkers (2010), detected higher levels of IDH1 in the wild type than in *TP*53 mutant cells. IDH1 correlates with histological Rosen grade and metastasis negatively. *TP*53 correlates with histological Rosen grade, metastasis and overall survival in clinical osteosarcoma biopsies. Osteosarcoma patients with high IDH1 expression have a very high p53 expression, so IDH1 may correlate with p53 and is a candidate biomarker for osteosarcoma [28].

Finally, a recent whole-genome sequencing study on osteosarcomas and chordomas describes a new process of cancer genome evolution termed chromothripsis. Rather than a multistep accumulation of unbalanced rearrangements, there is a single catastrophic genomic instability event that primarily affects a single chromosome [29]; maybe this could explain why *TP*53 mutations alone do not correlate to tumor progression. Moreover, to establish clinical implications of p53, it is also necessary to consider miRNA expression. They are generally deleted and/or disregulated in cancer. Certain microRNAs, (mir-34a, b, and c) can be transcriptionally transactivated by p53 [30,31]. On the other hand, mir-125b, negatively regulates *TP*53 expression [32]. So, it seems that not only *TP*53 mutations do affect its downstream functions, but also change in the related miRNAs need to be considered. Furthermore, p53 isoform variants originated from alternative splicing and the promoter usage can also have clinical implications [33]. In conclusion, the analysis of *TP*53 mutations status is the first step in the understanding of this important tumor suppressor gene in osteosarcomatumorigenesis. Further analysis, at the protein level and miRNA expression, needs to be performed aiming to establish a correlation between p53 and osteosarcoma clinical features.

5. Author's Contribution

LR: carried out the molecular genetic studies and participated in the design of the study and drafted the manuscript. CDB: participated in the design of the study, participated in the sequence alignment, performed the statistical analysis and coordination and draft the manuscript. MB conceived the study, and participated in its design and coordination. All authors read and approved the final manuscript.

6. Acknowledgments and Funding

REFERENCES

[1] Dorfman, H.D. and Czerniak, B. (1995) Bone cancers.

Cancer, **75**, 203-210.
http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<20
3::AID-CNCR2820751308>3.0.CO;2-V

[2] Dahlin, D.C. and Unni, K.K. (1977) Osteosarcoma of bone and its important recognizable varieties. *The American Journal of Surgical Pathology*, **1**, 61-72.
http://dx.doi.org/10.1097/00000478-197701010-00007

[3] Marina, N., Gebhardt, M., Teot, L. and Gorlick, R. (2004) Biology and therapeutic advances for pediatric osteosarcoma. *The Oncologist*, **9**, 422-441.

[4] Group, E.G.W. and Saeter, G. (2007) Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Annals of Oncology*: *Official Journal of the European Society for Medical Oncology/ESMO*, **18**, ii77-78.

[5] Simons, A., Schepens, M., Forus, A., Godager, L., van Asseldonk, M., Myklebost, O., *et al.* (1999) A novel chromosomal region of allelic loss, 4q32-q34, in human osteosarcomas revealed by representational difference analysis. *Genes*, *Chromosomes & Cancer*, **26**, 115-124.
http://dx.doi.org/10.1002/(SICI)1098-2264(199910)26:2<
115::AID-GCC3>3.0.CO;2-E

[6] Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K. and Vogelstein, B. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. *Science*, **249**, 912-915. http://dx.doi.org/10.1126/science.2144057

[7] Ozaki, T. and Nakagawara, A. (2011) p53: The attractive tumor suppressor in the cancer research field. *Journal of Biomedicine & Biotechnology*, **2011**, 603925.

[8] Vousden, K.H. and Lu, X. (2002) Live or let die: The cell's response to p53. *Nature reviews. Cancer*, **2**, 594-604. http://dx.doi.org/10.1038/nrc864

[9] Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., *et al*. (2007) Impact of mutant p53 functional properties on *TP*53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC *TP*53 database. *Human Mutation*, **28**, 622-629.
http://dx.doi.org/10.1002/humu.20495

[10] Olivier, M., Goldgar, D.E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. and Eeles, R.A. (2003) Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and *TP*53 genotype. *Cancer Research*, **63**, 6643-6650.

[11] Staples, O.D., Steele, R.J. and Lain, S. (2008) p53 as a therapeutic target. *The Surgeon*: *Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland*, **6**, 240-243.
http://dx.doi.org/10.1016/S1479-666X(08)80034-0

[12] Vousden, K.H. and Lane, D.P. (2007) p53 in health and disease. Nature reviews. *Molecular Cell Biology*, **8**, 275-283. http://dx.doi.org/10.1038/nrm2147

[13] Staib, F., Robles, A.I., Varticovski, L., Wang, X.W., Zeeberg, B.R., Sirotin, M., *et al*. (2005) The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. *Cancer Research*, **65**, 10255-10264.
http://dx.doi.org/10.1158/0008-5472.CAN-05-1714

[14] Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S.,

Eyfjord, J., *et al*. (2006) The clinical value of somatic *TP*53 gene mutations in 1794 patients with breast cancer. *Clinical Cancer Research*, **12**, 1157-1167.
http://dx.doi.org/10.1158/1078-0432.CCR-05-1029

[15] Perrone, F., Bossi, P., Cortelazzi, B., Locati, L., Quattrone, P., Pierotti, M.A., *et al*. (2010) *TP*53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. *Journal of Clinical Oncology*: *Official Journal of the American Society of Clinical Oncology*, **28**, 761-766.
http://dx.doi.org/10.1200/JCO.2009.22.4170

[16] Picci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., *et al*. (1985) Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. *Cancer*, **56**, 1515-1521.
http://dx.doi.org/10.1002/1097-0142(19851001)56:7<151
5::AID-CNCR2820560707>3.0.CO;2-6

[17] Kurvinen, K., Hietanen, S., Syrjanen, K. and Syrjanen, S. (1995) Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem. *Journal of Virological Methods*, **51**, 43-53.
http://dx.doi.org/10.1016/0166-0934(94)00099-3

[18] Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. and Cline, M.J. (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. *Proceedings of the National Academy of Sciences of the United States of America*, **84**, 7716-7719. http://dx.doi.org/10.1073/pnas.84.21.7716

[19] Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K. and Sekiya, T. (1989) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. *Proceedings of the National Academy of Sciences of the United States of America*, **86**, 2766-2770.
http://dx.doi.org/10.1073/pnas.86.8.2766

[20] Goto, A., Kanda, H., Ishikawa, Y., Matsumoto, S., Kawaguchi, N., Machinami, R., *et al.* (1998) Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. *Japanese Journal of Cancer Research*: *Gann*, **89**, 539-547.
http://dx.doi.org/10.1111/j.1349-7006.1998.tb03295.x

[21] Rosen, G., Loren, G.J., Brien, E.W., Ramana, L., Waxman, A., Lowenbraun, S., *et al*. (1993) Serial thallium-201 scintigraphy in osteosarcoma. Correlation with tumor necrosis after preoperative chemotherapy. *Clinical Orthopaedics and Related Research*, **293**, 302-306.

[22] Radig, K., Schneider-Stock, R., Oda, Y., Neumann, W., Mittler, U. and Roessner, A. (1996) Mutation spectrum of p53 gene in highly malignant human osteosarcomas. *General & Diagnostic Pathology*, **142**, 25-32.

[23] Gokgoz, N., Wunder, J.S., Mousses, S., Eskandarian, S., Bell, R.S. and Andrulis, I.L. (2001) Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. *Cancer*, **92**, 2181-2189.
http://dx.doi.org/10.1002/1097-0142(20011015)92:8<218
1::AID-CNCR1561>3.0.CO;2-3

[24] Tsuchiya, T., Sekine, K., Hinohara, S., Namiki, T., No-

bori, T. and Kaneko, Y. (2000) Analysis of the p16INK4, p14ARF, p15, *TP*53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. *Cancer Genetics and Cytogenetics*, **120**, 91-98. http://dx.doi.org/10.1016/S0165-4608(99)00255-1

[25] Patino-Garcia, A. and Sierrasesumaga, L. (1997) Analysis of the p16INK4 and *TP*53 tumor suppressor genes in bone sarcoma pediatric patients. *Cancer Genetics and Cytogenetics*, **98**, 50-55. http://dx.doi.org/10.1016/S0165-4608(96)00397-4

[26] Lonardo, F., Ueda, T., Huvos, A.G., Healey, J. and Ladanyi, M. (1997) p53 and MDM2 alterations in osteosarcomas: Correlation with clinicopathologic features and proliferative rate. *Cancer*, **79**, 1541-1547. http://dx.doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y

[27] Wunder, J.S., Gokgoz, N., Parkes, R., Bull, S.B., Eskandarian, S., Davis, A.M., *et al.* (2005) *TP*53 mutations and outcome in osteosarcoma: A prospective, multicenter study. *Journal of Clinical Oncology*: *Official Journal of the American Society of Clinical Oncology*, **23**, 1483-1490. http://dx.doi.org/10.1200/JCO.2005.04.074

[28] Hu, X., Yu, A.X., Qi, B.W., Fu, T., Wu, G., Zhou, M., *et al.* (2010) The expression and significance of IDH1 and p53 in osteosarcoma. *Journal of Experimental & Clinical Cancer Research*: *CR*, **29**, 43. http://dx.doi.org/10.1186/1756-9966-29-43

[29] Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., *et al*. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell*, **144**, 27-40. http://dx.doi.org/10.1016/j.cell.2010.11.055

[30] Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C.J., *et al*. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Molecular Cell*, **26**, 745-752. http://dx.doi.org/10.1016/j.molcel.2007.05.010

[31] He, L., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., *et al.* (2007) A microRNA component of the p53 tumour suppressor network. *Nature*, **447**, 1130-1134. http://dx.doi.org/10.1038/nature05939

[32] Le, M.T., The, C., Shyh-Chang, N., Xie, H., Zhou, B., Korzh, V., Lodish, H.F. and Lim, B. (2009) MicroRNA-125b is a novel negative regulator of p53. *Genes & Development*, **23**, 862-876. http://dx.doi.org/10.1101/gad.1767609

[33] Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K. and Lane, D.P. (2005) p53 isoforms can regulate p53 transcriptional activity. *Genes & Development*, **19**, 2122-2137. http://dx.doi.org/10.1101/gad.1339905

List of Abbreviations

*TP*53: tumor protein p53;
IARC International Agency for Research on Cancer;
DNA: Deoxyribonucleic acid;
HNSCC: head and neck squamous cell carcinoma;

PCR: polymerase chain reaction;
SSCP: Single Strand Conformation Polymorphism;
Avh: accumulated volts per hour;
IDH1: isocitrate dehydrogenase.